FERRING PHARMACEUTICALS TO ACQUIRE MARKETING RIGHTS FOR DDAVP® (DESMOPRESSIN) PRODUCT PORTFOLIO FROM SANOFI

PARSIPPANY, N.J., Oct. 22, 2014 /PRNewswire-USNewswire/ – Ferring Pharmaceuticals is pleased to announce that the company has acquired DDAVP® (desmopressin acetate) from Sanofi. Ferring is the original developer of the drug desmopressin and has a long-standing history in peptide-based specialty care.

"The return of DDAVP to its roots at Ferring is a welcome addition to our portfolio of products and affirms our commitment to supporting a wide range of disorders with high unmet medical need," said Aaron Graff, President & COO, Ferring Pharmaceuticals Inc. "As a result of this acquisition, distribution of DDAVP will be transferred from Sanofi to Ferring immediately."

DDAVP is available in the following formulations: DDAVP® Tablets, DDAVP® Nasal Spray, DDAVP® Rhinal Tube and DDAVP® Injection.

About DDAVP®
Ferring has a long-standing interest in the area of endocrinology and pediatric urology, which began with the development of desmopressin (desmopressin acetate) in the mid-1970s.

All desmopressin formulations (DDAVP® Tablets, DDAVP® Nasal Spray, DDAVP® Rhinal Tube, and DDAVP® Injection) are approved by the U.S. Food and Drug Administration (FDA).

You are encouraged to report side effects of prescription drugs. Contact Ferring at 1-888-FERRING (1-888-337-7464) or call 1-800-FDA-1088 or visit www.fda.gov/medwatch.

About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics, and urology. For more information, call 1-888-FERRING (1-888-337-7464); visit www.FerringUSA.com.

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.